je.st
news
Home
› Evotec And Ex Scientia Announce Partnership To Discover Bispecific Small Molecule Immuno-Oncology Therapeutics
Evotec And Ex Scientia Announce Partnership To Discover Bispecific Small Molecule Immuno-Oncology Therapeutics
2016-05-03 03:19:19| drugdiscoveryonline News Articles
Evotec AG and ex scientia Ltd (Dundee, UK) recently announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies
Tags: small
partnership
discover
announce
Category:Biotechnology and Pharmaceuticals